- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2014 (2014), Article ID 429031, 14 pages
The Role of Physical Exercise in Inflammatory Bowel Disease
1Department of Ergonomics and Exercise Physiology, Faculty of Health Sciences, Jagiellonian University Medical College, 31-531 Cracow, Poland
2Gastroenterology Clinic, Jagiellonian University Medical College, 31-501 Cracow, Poland
3Department of Physiology, Faculty of Medicine Jagiellonian University Medical College, 31-531 Cracow, Poland
Received 1 January 2014; Revised 25 February 2014; Accepted 5 March 2014; Published 30 April 2014
Academic Editor: Lars L. Andersen
Copyright © 2014 Jan Bilski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We reviewed and analyzed the relationship between physical exercise and inflammatory bowel disease (IBD) which covers a group of chronic, relapsing, and remitting intestinal disorders including Crohn’s disease (CD) and ulcerative colitis. The etiology of IBD likely involves a combination of genetic predisposition and environmental risk factors. Physical training has been suggested to be protective against the onset of IBD, but there are inconsistencies in the findings of the published literature. Hypertrophy of the mesenteric white adipose tissue (mWAT) is recognized as a characteristic feature of CD, but its importance for the perpetuation of onset of this intestinal disease is unknown. Adipocytes synthesize proinflammatory and anti-inflammatory cytokines. Hypertrophy of mWAT could play a role as a barrier to the inflammatory process, but recent data suggest that deregulation of adipokine secretion is involved in the pathogenesis of CD. Adipocytokines and macrophage mediators perpetuate the intestinal inflammatory process, leading to mucosal ulcerations along the mesenteric border, a typical feature of CD. Contracting skeletal muscles release biologically active myokines, known to exert the direct anti-inflammatory effects, and inhibit the release of proinflammatory mediators from visceral fat. Further research is required to confirm these observations and establish exercise regimes for IBD patients.
Chronic inflammation plays a central role in the pathology of many diseases. For some, such as rheumatoid arthritis (RA), inflammatory bowel diseases (IBD), and asthma, the most characteristic is a massive infiltration of inflammatory cells at the site of disease activity and the local presence of inflammatory mediators in elevated concentrations as well as their abundance in the systemic circulation. These may lead to pathological disorders in organs distant from the primary inflammatory lesions probably evoked by systemic inflammatory mediators .
Ulcerative colitis (UC) and Crohn’s disease (CD) are the two main forms of IBD characterized by a cyclic nature, alternating between active and quiescent states impairing patients’ quality of life. Although the inflammatory process in CD is typically transmural and can affect any part of the gastrointestinal tract, the UC affects only the colon and is limited to the mucosa and superficial submucosa . Anorexia, malnutrition, altered body composition, and development of mesenteric white adipose tissue (mWAT) hypertrophy (accumulation of intra-abdominal mWAT) are other well-known features of IBD and especially of CD . Additionally, apart from intestinal changes in CD, the secondary disorders in distant organs such as skin lesion, arthritis, osteoporosis, eye, and liver disorders may frequently occur . Association between inflammation and carcinogenesis is well proven and IBD is an important risk factor for the development of colon cancer . Although progress has been made in understanding the IBD, its etiology is still unknown. The accepted theory suggests that a combination of environmental agents and a dysfunctional mucosal immune system in genetically susceptible individuals could lead to the development of either CD or UC [4, 5]. It was established that CD is a Th1 cytokine-mediated disease characterized by increased production of interferon (IFN-) γ, whereas UC most likely resembles a modified Th2 profile, characterized by increased production of interleukin- (IL-) 5 production and normal IFN-γ production . Cytokines, such as TNF-α, IL-1β, and IL-6 are more promiscuous in their function because they are associated with both forms of IBD to a lesser or greater degree [6, 7]. Each of these cytokines can activate NF-κB and the mitogen-activated protein kinases, thereby initiating a cascade of “downstream” proinflammatory effects that are the immediate prerequisites of tissue and organ pathology in IBD . Recently, TNF-like weak inducer of apoptosis (TWEAK), the TNF super family (TNFSF) member, has appeared as a new factor in the inflammatory processes and its crucial role in IBD has been proposed [8–10]. Its actions are mediated by binding to fibroblast growth factor-inducible 14 (Fn14), surface receptor that has been linked to several intracellular signaling pathways, including the nuclear factor-κB (NF-κB) inflammatory pathway . Fn14 can be upregulated on intestinal epithelial cells, most probably by their exposure to microbial or inflammatory products and contribute to failure of the mucosal barrier; the induction of IEC-derived mediators that promote chronic inflammation and shape gut immunity against commensally bacteria . Interestingly, this expression of Fn14 is upregulated in CD patients .
The concept of exercise training could cover heterogeneous interventions that differ in type (e.g., endurance versus resistance training, acute versus chronic exercise), intensity, frequency, and duration. Structured exercise training could consist of aerobic exercise, resistance training, or a combination of both. In contrast to structured exercise training, physical activity is defined as any bodily movement produced by skeletal muscle contractions resulting in increased energy expenditure .
The well-documented observations that physical activity is inversely correlated with systemic low-level inflammation lead to suggestion that the anti-inflammatory activity induced by regular exercise may be responsible for some beneficial health effects in patients with chronic diseases . However, the intensive exercise may induce a transient mild systemic inflammation and increased level of cytokines and these adverse effects depend on intensity and duration of exercise. Following prolonged and strenuous exercise, the function of the immune system is impaired for several hours [14, 15], but on the other hand, the regular exercise training has been shown to increase resistance to infections [16–19].
The possible beneficial effects of physical activity on the gastrointestinal tract have been so far little studied. It is known that intensive exercise such as long distance running and triathlons could cause nausea, heartburn, diarrhea, or even gastrointestinal bleeding and marathon runners suffer from “runner’s ischemic colitis,” involving bloody diarrhea, fatigue, and fever . The involvement of physical activity in prevention of colon cancer  has been well proven, but the effect of physical activity on IBD is less documented and the importance of exercise as adjunct anti-inflammatory therapy has been suggested [22–24]. There is a general commitment that IBD patients could benefit from physical training because regular exercise could improve psychological health and reduce some disease symptoms and complications . However, from our current knowledge on exercise in relation to immune functions, cytokines network, and in particular, the secretory role of contracting muscles, one concludes that a relatively small attention has been addressed to mechanisms of action of regular exercise in patients with a chronic inflammatory disease like IBD, in which immune response is impaired. Most studies have examined the beneficial effects of exercise in terms of quality of life and general fitness but relatively few studied effects of training on disease pathogenesis and measures of inflammation and evidence-based recommendations could not yet be made for this disease [22–25].
Taking into the account the lack of sufficient evidence-based exercise guidelines for those subjects who suffer from IBD and that physical activity is recommended for such patients as a complementary medical therapy, the purpose of the review was to evaluate published human and experimental research studies focusing on physical activity and IBD.
Particular aims of the present review were to update the literature on physical activity in IBD and to evaluate (1) whether physical activity in the preillness period could influence onset of IBD, (2) impact of exercise on IBD, and (3) overview on selection of types and intensities of exercise in individuals suffering from this disease and how exercise affects experimental models of this disease. In discussion, we focused on potential mechanisms of beneficial action of physical training.
2.1. Search Strategy
We searched the following electronic databases up to January 2014: MEDLINE (accessed by PubMed), Google Scholar, Web of Science, PEDRo, and IBD/FBD Group Specialized Register (June 2013). The following search string was entered into each database using MeSH terms, appropriate alternatives, and Boolean operators: inflammatory bowel disease, Crohn’s disease, or ulcerative colitis and exercise, physical activity, physical fitness, or physical training. Variations of the above search strategy were used to search the databases other than Medline.
2.2. Study Selection
Two reviewers (JB and TB) independently assessed study eligibility and the full-text articles were then examined. Bibliographies from existing articles were screened manually. Only fully published papers were reviewed. Figure 1 provides a flowchart of study selection. In Figure 2, the insight into mechanism of crosstalk between skeletal muscle, adipose tissue and the inflammation in the gut is presented.
3.1. Exercise in the Preillness Period
The incidence and prevalence of IBD rapidly increased in last years in developed countries and the rise witnessed in the rest of the world closely correlates with adopting a western lifestyle . These observations support the notion that a variety of environmental factors contribute to the pathogenesis of intestinal diseases . In developed countries, peoples’ lifestyle has changed significantly, being affected by serious modifications in dietary habits and physical inactivity . Those changes in lifestyle may have a bearing on the course of the disease. Some studies have examined the effect of lifestyle and particularly physical activity as supposed by causal agents for the onset of IBD (Table 1).
The protective role of physical activity against the onset of IBD was first postulated by Sonnenberg  who found that occupations characterized by outdoor physical work appeared to be protective compared with those occupations classified as sedentary in retrospective study in male and female German workers. In small () case-control study Persson et al.  reported an inverse association between physical activity and CD (but not UC) onset in a Swedish cohort. A prospective study which followed two cohorts, each of more than 2.3 million persons in Denmark, for 5 or 10 years, found a small association between sedentary office work lifestyle and the onset of IBD . In 1998, a study by Klein et al.  determined that IBD patients () had lower levels of physical activity during their preillness period than clinic controls (; ). IBD patients had lower levels of physical activity during their preillness period compared to clinic but not population controls. Cucino and Sonnenberg  examined the occupations of IBD mortalities between 1991 and 1996 in 2399 CD and 2419 UC patients in USA and found that IBD mortality was low in occupations associated with manual work and relatively high in sedentary occupations. When Halfvarson et al.  studied environmental factors in a population-based Swedish-Danish twin cohort using the cotwin control method, they found no significant differences between the twins in physical activity before the diagnosis of IBD.
In a recent the European Prospective Investigation into Cancer and Nutrition study, 300,724 participants were recruited into and the cohort was monitored identifying participants who developed CD or UC, but physical activity did not show any association with UC or CD . In case-control study in Slovakia  which included 338 patients (190 CD, 148 UC) and 355 controls CD and UC, an onset of IBD was inversely associated with physical activity. In another recent study in two large prospective cohorts of US women (194 711 women) the association between physical activity and risk of ulcerative colitis and Crohn’s disease was studied . Women enrolled in this prospective cohort study provided data on physical activity since 1984 in Nurses’ Health Study and 1989 in Nurses’ Health Study II and followed up through 2010 (USA). Physical activity was found inversely associated with risk of Crohn’s disease but not of ulcerative colitis.
3.2. Impact of Exercise on IBD
The physical activity has been used in IBD as an adjunctive therapy regime, although the effectiveness of exercise on disease activity has not been well described and the mechanisms of its potential beneficial effects are poorly understood [25, 37]. Studies that examined the effect of exercise on IBD involved mainly patients with quiescent state of disease (Table 2). In sedentary patients with inactive or mildly active CD, the moderate exercise by means of walking program or yoga led to significant improvement in measures of quality of life and stress levels [38–41]. The moderate-intensity exercise was well tolerated by IBD patients who are in remission and did not provoke subjective symptoms or changes in gastrointestinal parameters [42, 43]. Ploeger et al.  tested the effect of moderate intensity continuous exercise and high intensity intermittent exercise in youth with CD and concluded that such patients can engage in different types of exercise without a significant exacerbation of the disease. The results of the UK online survey have shown that a majority of respondents were undertaking regular exercise which was found to be beneficial for the symptoms of IBD. However, most of the respondents were prone to stop exercising at some point because of their increased incidents of complaints on severity of symptoms .
3.3. Intestinal Disorders and Physical Activity in Experimental Animals
Some of these aspects were also observed at experimental conditions because in mouse model of colitis, the forced treadmill exercise training exacerbated inflammation and increased mortality, while voluntary wheel training was protective in this rodent model . This effect of treadmill exercise was accompanied by increased morbidity due to excessive diarrhea episodes and mortality . In contrast, thirty days of voluntary wheel running attenuated inflammatory gene expression in the distal colon reduced the diarrhea incidences and protected mice from colitis-induced morbidity . Moreover, the induction of experimental colitis by TNBS or dextran sulfide administration caused a significant increase in the TNF-content in the colonic mucosa and submucosa [47, 48]. In another study, the long-term physical exercise of 6-week running attenuated the colonic TNF-α protein content indicating an anti-inflammatory impact of exercise training . Some studies have shown that both forced treadmill and voluntary wheel exercise training can exert an anti-inflammatory effect in the inflamed colon [48–51]. In study by Saxena et al.  exercise training (treadmill running at gradually increasing speeds 10, 12, 16, and 18 m/min and a 5% incline for 20 min) significantly decreased proinflammatory cytokines in the adiponectin knockout mice with dextran sodium sulfate induced experimental colitis. In another study moderate exercise (30 min per day of swimming) attenuated chronic stress-induced intestinal barrier dysfunction in mice, possibly due to augmentation of antimicrobial responses in the small intestine . A summary of experimental studies on the experimental IBD and exercise depending on its intensity is shown in Table 3.
These findings point to the important role for exercise in the adjunct treatment of IBD in humans. Since IBD affects up to 0.25% of the US population or ~750.000 people; thus it is considered as a significant problem . The fact that selection of a proper dosage of the exercise was able to alleviate colitis symptoms, reduce colon inflammation, and counteract the adverse effects associated with pharmacological therapy (e.g., 5-aminosalicylic acid) [47–49] seems to be of key interest in convincing medical professionals to adopt the life style strategy as an adjunct therapy in their IBD treatment.
The protective effect of exercise may to some extent be attributed to its anti-inflammatory effect and it may mediate via muscle-derived peptides, the so-called “myokines” . Contracting skeletal muscles release myokines like IL-15 with endocrine effects, mediating direct anti-inflammatory effects, and/or specific effects on visceral fat . Possible role of a new myokine irisin which is released during exercise and act on the white fat cells is still studied .
Creeping fat in patients with Crohn’s disease refers to hypertrophy of the mesenteric fat tissue located around the inflamed parts of the intestine  and recent research suggests that this fat wrapping contribute actively to disease severity and may influence onset of complications [56–63]. Accumulating evidence suggests that mesenteric white adipose tissue (mWAT), composed of not only fat but also macrophages and T lymphocytes, plays an important role as the source of inflammation and releases various inflammatory factors such as cytokines and chemokines [64–68]. This mesenteric fat which is present from the onset of disease is associated with overexpression of TNF-α, leptin, and other adipokines and correlates with the severity of intestinal inflammation and tissue injury, suggesting an important role for adipose tissue in the intestinal inflammatory process in CD [55, 62, 69–71]. The intestinal luminal leptin, a cytokine produced by adipocytes, is increased in CD and can upregulate NF-κB expression in colonic epithelial cells [58, 72–74]. Leptin is considered to be a proinflammatory cytokine  and directly regulates production of several cytokines, particularly those released from T cells. It increases IL-2 and interferon γ production while decreasing IL-4 levels . An overexpression of leptin mRNA in mWAT was reported in IBD patients, indicating that leptin might participate in the inflammatory process by enhancing mesenteric TNF-α expression [75, 76] and leptin levels have been shown to be significantly higher in mesenteric adipose tissue from CD patients, than in patients with noninflammatory disease [58, 72]. Experimental colitis in rats resulted in elevated circulating leptin levels which correlate with the degree of inflammation and the development of anorexia  and leptin antagonist ameliorated the development of chronic experimental colitis . Another adipokine, adiponectin, which is considered anti-inflammatory, has a structure similar to TNF-α but antagonizes its effects by reducing secretion and attenuating the biological actions by competing for the receptor [79–81]. Divergent data have been presented about circulating levels of adiponectin in patients with IBD [72, 74, 80, 82–86]. Adiponectin production is enhanced in hypertrophied mWAT which remained in contact with the intestine of CD patients, and this increase may be specifically related to inflammation and the presence of this fat wrapping [79, 87]. A role for hypertrophied mesenteric fat tissue as a barrier to the inflammatory process was postulated in other studies [86, 88, 89]. However, recent observations of lower levels of serum and mesenteric adiponectin in active CD patients compared with those in remission suggest a defective regulation of anti-inflammatory pathways in CD pathogenesis . The impaired balance between proinflammatory and anti-inflammatory factors due to an increase in secretion of TNF-α, leptin, and the release of chemoattractant protein-1 (MCP-1) and the decreased production of adiponectin could result in macrophage accumulation in adipocytes and an inflammatory transformation of the visceral adipose tissue, leading to the appearance of creeping fat . Adipocytokines and macrophage mediators secreted by the creeping fat could further increase the intestinal inflammatory process, leading to mucosal ulcerations along the mesenteric border, a typical feature of CD [82, 90]. The massive cytokine production in the inflamed colon, in addition to translocalizing bacteria, could further induce the production of proinflammatory mediators in the adjacent adipose tissue, thus inducing a vicious cycle, in which inflammatory conditions in the intestine and the mesenteric fat support each other [88, 91]. Cytokine overproduction and particularly leptin by mesenteric fat could lead to anorexia, another feature present in CD .
4.1. Importance of Skeletal Muscle Crosstalk with the Fat Tissue and the Gut in Protection against Intestinal Disorders
Exercise could improve nutrient metabolism in skeletal muscle as well as vascular function and microcirculation, but the accumulated so far evidence suggests that the protective effect of exercise may to some extent be ascribed to its anti-inflammatory effect. Exercise may exert its anti-inflammatory effect via a reduction in visceral fat mass and/or by induction of an anti-inflammatory environment with each bout of exercise. Such effects may in part be mediated via muscle-derived peptides . If the endocrine and paracrine functions of the muscle are not stimulated through contractions, this will cause dysfunction of several organs and tissues of the body as well as an increased risk of chronic inflammatory diseases [54, 92, 93]. As mentioned before, myokines may balance and counteract the effects of adipokines taking part in crosstalk between skeletal muscle and adipose tissue [37, 54]. The secreted myokines are associated with muscle function revealing a novel secretory proteins released from skeletal muscles during exercise that also have been shown to be impaired with ageing.
The prototype myokine, IL-6, appears to be able to mediate metabolic effects as well as anti-inflammatory effects. In response to muscle contractions muscle fibres express the myokine IL-6, which exerts its effects both locally within the muscle and in several distant organs [54, 94]. It has been accepted that the rise in IL-6 level was a consequence of immune response to local damage observed during exercise. Nowadays it is known that muscle is unique in its ability to produce IL-6 during contraction in completely TGF-independent mode. This suggests a major role for this cytokine in a regulation of metabolism rather than acting as an inflammatory mediator [95, 96]. It was shown that IL-6 released by muscle during exercise can mediate release of GLP-1 from intestinal L cells (and from pancreatic A cells) which in turn acts as an incretin causing insulin release providing an evidence that there is possible crosstalk between adipocytes, muscle, and pancreas responsible for energy homeostasis . The exercise increased dramatically level of IL-6 in mice and induced a parallel marked rise in GLP-1 . Glucagon-like peptides are trophic growth factors that enhance repair of damaged intestinal mucosa and the release of these factors could be in part responsible for beneficial effect of exercise [97–100].
IL-15 that is expressed in human skeletal muscle has been identified as an anabolic factor in muscle growth and has been implicated in muscle-fat crosstalk . It was demonstrated that IL-15 mRNA levels were upregulated in human skeletal muscle following a bout of strength training, suggesting that IL-15 may accumulate within the muscle as a consequence of regular training . Interestingly, a decrease in visceral fat mass, but not subcutaneous fat mass, was observed, when IL-15 was overexpressed in murine muscle. Also the elevated circulating levels of IL-15 resulted in significant reductions in body fat and increased bone mineral content [102, 103]. In a recent study, Boström and colleagues  identified a new myokine which they called irisin. This myokine is released during exercise and cause the transformation of white fat cells into bright cells (brown-in-white fat cells), with a phenotype similar to that of brown fat cells [104, 105]. In humans, plasma levels of irisin after 10 weeks of regular endurance training were significantly and markedly increased. It was suggested that irisin could be therapeutic for human metabolic disease, obesity, and other disorders in which the exercise is beneficial [104, 105]. Recently, a new myokine secreted protein acidic and rich in cysteine (SPARC) was functionally characterized . SPARC had increased in skeletal muscle and had been secreted into the circulation in response to exercise. The release of SPARC was linked with inhibition of colon tumorigenesis by increasing apoptosis . SPARC is a secreted matricellular glycoprotein that is involved in the development, remodeling, and tissue repair by modulating cell-cell and cell-matrix interactions as well as other functions such as antitumorigenesis action . Interestingly, a single bout of exercise rapidly increased SPARC blood plasma and muscle levels suggesting that the muscle cells secrete this myokine into the circulation. This exercise-induced increase in SPARC appeared to be muscle-specific because no increase was observed in other organs where SPARC was found to be abundant .
Depletion of skeletal muscle mass, decreased muscle strength and endurance, and reduced height velocity in children are characteristic features in IBD [2, 107–109]. Particularly in CD, muscle mass and function are reduced compared to healthy controls, potentially resulting in disability . Mechanisms contributing to muscle impairment and thus potential therapeutic targets are poorly understood. The IBD-related growth failure and decreased muscle mass could be the result of a variety of mechanisms including decreased nutrient intake, malabsorption of ingested nutrients, and increased metabolic rate but also could be attributed to elevated concentrations of inflammatory cytokines, decreased level of insulin-like growth factor 1 (IGF-1), and treatment with corticosteroids . Both plasma IGF-I and muscle IGF-I are decreased in response to diverse inflammatory insults that accelerate the loss of muscle protein . The function of the GH-insulin-like growth factor- (IGF-) I axis depends on finely tuned mechanisms, which can be impaired by inflammatory cytokines released from pathologically modified mWAT. Inflammatory cytokines, notably TNF-α, reduce liver GH receptor numbers and seem to be responsible for hepatic GH resistance and decrease of circulating IGF-I level that leads to growth inhibition and decrease of lean body mass (LBM) [112–114]. Recent study has shown an attenuated muscle hypertrophy pathway in CD compared with controls particularly in human subjects with lower serum vitamin D3 and lower physical activity indices. This reduced muscle mass in CD may be explained, in part, by impaired activation of muscle protein synthesis pathways, in particular IGF1-Akt pathway. Finally, it was concluded that the normal vitamin D levels and regular exercise may be protective in CD . Studies performed on rats with experimental colitis have demonstrated inhibitory effects of inflammation on IGF-I generation and the linear growth, the mechanisms independent of malnutrition [115, 116]. Impaired function of satellite cells is another link between impaired insulin/IGF-I signaling and muscle protein loss . It was shown that resistance training can prevent and even reverse the progression of sarcopenia .
Accumulating evidence suggests that peroxisome proliferator-activated receptor γ coactivator α (PGC-1α) and TWEAK-Fn14 system are key regulators of skeletal muscle mass in various catabolic states. While the activation of TWEAK-Fn14 signaling causes muscle wasting, PGC-1α preserves skeletal muscle mass. Inflammatory reactions during IBD favor TWEAK-Fn14 system when physical exercise possibly exhibits a counteractive effect [9, 10, 118, 119].
4.2. Other Benefits of Exercise for IBD Patients
Beside the anti-inflammatory actions, several other benefits of physical exercise in IBD patients have been suggested. Ankylosing spondylitis has been specifically associated with IBD, but the exercise therapy improved the flexibility strength and reduced pain of the joints . IBD is associated with decreased bone mineral density and increased risk of osteoporosis  and preventive role of exercise has been proposed [122–124]. It was demonstrated that physical exercise can increase bone mineral density (BMD) in CD and may reduce the risk of osteoporotic fracture . The pediatric patients, particularly with Crohn’s disease, are at risk for extra intestinal manifestation including growth failure, weight loss, and anemia. Additional beneficial effect of exercise could be amelioration of accompanying anorexia, possibly by modification of the release of adipokines and ghrelin . The reduced food intake in IBD could be caused by abdominal pain, diarrhea and incontinence, surgery, nausea, depression, or a feeling of general unwellness but satiety control in IBD patients is also probably modulated by availability of inflammatory cytokines like leptin which suppresses appetite, reducing the motivation to eat [126–128]. The fatigue is a commonly observed symptom in CD, even in quiescent state of the disease and this effect is probably mediated, at least in part, by cytokines [93, 129]. Role of exercise in reduction of fatigue in chronic diseases including IBD was emphasized [93, 129, 130]. IBD patients have higher levels of daily stress and a lower quality of life compared with general population but also with those patients who suffer from other chronic diseases [27, 28]. The beneficial role of exercise in such cases has been proven [131, 132].
The effect of exercise on different immune parameters could depend on its intensity, duration, and the type of exercise (e.g., endurance versus resistance training, acute versus chronic exercise). Systematic exercise may be beneficial for CD patients for its anti-inflammatory and anabolic properties. However, acute, strenuous exercise could lead to release of inflammatory cytokines that could be involved in the pathology of CD and even induce an exacerbated inflammatory response .
Previous studies show that low-intensity exercise is well tolerated in IBD patients. Moreover, this exerted a beneficial effect on course of this disease. In guidelines created in 1998 specifically for IBD patients, physical exercise was recommended for general health to counteract muscle wasting and improve bone density . An aerobic activity for 20 min to 60 min two to five days every week, accompanied by resistance exercise at least twice per week was recommended. The guidelines, however, were not based on actual research. In recent review authors proposed similar recommendations and suggested that two main types of physical interventions should be recommended for CD patients, namely, the aerobic activity and the muscular resistance training .
4.3. High-Intensity Physical Training in the Treatment of IBD
Single bouts of exercise could activate the same inflammatory mediators as those involved in pathology of IBD. It is generally accepted that high intensity exercise may lead to an acute although transient, exacerbation of inflammation, and the symptoms of IBD. Therefore, such training is generally not recommended for IBD patients . However, such recommendations are not well supported by research studies. Only one study which examined the effect of high intensity intermittent exercise in pediatric patients concluded that that such intense exercise is well tolerated .
The generally accepted model for exercise prescription in many chronic inflammatory diseases was moderate-intensity-aerobic continuous training with such proven benefits like increase in exercise capacity, the amelioration of stress, and an increase in quality of life. Recently, however, a body of evidence has indicated that high intensity interval training can be performed safely and lead to similar health effects compared to longer, continuous exercise and is less associated with release of inflammatory mediators [134, 135]. Such exercise program may be particularly beneficial for children with CD, not only to improve exercise capacity, but also because of anabolic action and stimulation of growth and development [136, 137]. On the other hand moderate intensity exercise could be more effective than high intensity in stimulation of release of myokines as shown by Yeo et al. .
Although anti-inflammatory pharmaceutical treatments are beneficial in reducing IBD symptoms, they are often related to serious side effects and their efficacy is not complete. IBD patients continue to have physical and psychological complaints, impairing their quality of life. Preliminary studies demonstrate that moderate exercise has no negative health effects and may diminish some symptoms of IBD. The exercise is recommended also because it could counteract some IBD specific complications by improving immunological response, psychological health, nutritional status, bone mineral density and reversing the decrease of muscle mass and strength. Recent research suggests that the beneficial effects of regular exercise may be in part due to the anti-inflammatory effects of myokines released due to skeletal muscle contractions. Further studies are definitely required to confirm these observations and establish exercise regimes for different IBD patient groups. Additional basic and clinical research with exercise of higher intensities is also needed to establish a potential acceptable limit for physical activity in IBD patients.
Conflict of Interests
The authors declare that they have no conflict of interests.
This paper and own authors data described in this paper were supported by the Grant from National Center of Science in Poland (Contract no. NCN-umo-2013/09/B/NZ4/01566).
- K. M. Beavers, T. E. Brinkley, and B. J. Nicklas, “Effect of exercise training on chronic inflammation,” Clinica Chimica Acta, vol. 411, no. 11-12, pp. 785–793, 2010.
- F. Shanahan, “Crohn's disease,” The Lancet, vol. 359, no. 9300, pp. 62–69, 2002.
- J. Terzić, S. Grivennikov, E. Karin, and M. Karin, “Inflammation and colon cancer,” Gastroenterology, vol. 138, no. 6, pp. 2101–2114, 2010.
- D. C. Baumgart and W. J. Sandborn, “Inflammatory bowel disease: clinical aspects and established and evolving therapies,” The Lancet, vol. 369, no. 9573, pp. 1641–1657, 2007.
- R. B. Sartor, “Mechanisms of disease: Pathogenesis of Crohn's disease and ulcerative colitis,” Nature Clinical Practice Gastroenterology and Hepatology, vol. 3, no. 7, pp. 390–407, 2006.
- W. Strober and I. J. Fuss, “Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases,” Gastroenterology, vol. 140, no. 6, pp. 1756–1767, 2011.
- W. Strober, F. Zhang, A. Kitani, I. Fuss, and S. Fichtner-Feigl, “Proinflammatory cytokines underlying the inflammation of Crohn's disease,” Current Opinion in Gastroenterology, vol. 26, no. 4, pp. 310–317, 2010.
- T. Dohi, A. Borodovsky, P. Wu et al., “TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis,” Gastroenterology, vol. 136, no. 3, pp. 912–923, 2009.
- T. Dohi and L. C. Burkly, “The TWEAK/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases: focus on inflammatory bowel diseases,” Journal of Leukocyte Biology, vol. 92, no. 2, pp. 265–279, 2012.
- A. Son, T. Oshio, Y. I. Kawamura, et al., “TWEAK/Fn14 pathway promotes a T helper 2-type chronic colitis with fibrosis in mice,” Mucosal Immunology, vol. 6, no. 6, pp. 1131–1142, 2013.
- L. C. Burkly and T. Dohi, “The TWEAK/Fn14 pathway in tissue remodeling: for better or for worse,” Advances in Experimental Medicine and Biology, vol. 691, pp. 305–322, 2011.
- C. J. Caspersen, K. E. Powell, and G. Christenson, “Physical activity, exercise and physical fitness: definitions and distinctions for health-related research,” Public Health Reports, vol. 100, no. 2, pp. 126–131, 1985.
- K. R. Wilund, “Is the anti-inflammatory effect of regular exercise responsible for reduced cardiovascular disease?” Clinical Science, vol. 112, no. 11-12, pp. 543–555, 2007.
- L. Hoffman-Goetz and B. K. Pedersen, “Exercise and the immune system: a model of the stress response?” Immunology Today, vol. 15, no. 8, pp. 382–387, 1994.
- B. K. Pedersen and D. C. Nieman, “Exercise immunology: integration and regulation,” Immunology Today, vol. 19, no. 5, pp. 204–206, 1998.
- L. Fitzgerald, “Exercise and the immune system,” Immunology Today, vol. 9, no. 11, pp. 337–339, 1988.
- S. A. Bartram, R. T. Peaston, D. J. Rawlings, D. Walshaw, R. M. Francis, and N. P. Thompson, “Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn's disease,” World Journal of Gastroenterology, vol. 12, no. 35, pp. 5680–5686, 2006.
- N. P. Walsh, M. Gleeson, D. B. Pyne et al., “Position statement part two: maintaining immune health,” Exercise Immunology Review, vol. 17, pp. 64–103, 2011.
- N. P. Walsh, M. Gleeson, R. J. Shephard, et al., “Position statement. Part one: immune function and exercise,” Exercise Immunology Review, vol. 17, pp. 6–63, 2011.
- G. W. K. Ho, “Lower gastrointestinal distress in endurance athletes,” Current Sports Medicine Reports, vol. 8, no. 2, pp. 85–91, 2009.
- J. Kruk and U. Czerniak, “Physical activity and its relation to cancer risk: updating the evidence,” Asian Pacific Organization for Cancer Prevention, vol. 14, no. 7, pp. 3993–4003, 2013.
- V. Ng, W. Millard, C. Lebrun, and J. Howard, “Exercise and Crohn's disease: speculations on potential benefits,” Canadian Journal of Gastroenterology, vol. 20, no. 10, pp. 657–660, 2006.
- C. A. Pérez, “Prescription of physical exercise in Crohn's disease,” Journal of Crohn's and Colitis, vol. 3, no. 4, pp. 225–231, 2009.
- N. Narula and R. N. Fedorak, “Exercise and inflammatory bowel disease,” Canadian Journal of Gastroenterology, vol. 22, no. 5, pp. 497–504, 2008.
- N. Packer, L. Hoffman-Goetz, and G. Ward, “Does physical activity affect quality of life, disease symptoms and immune measures in patients with inflammatory bowel disease? A systematic review,” Journal of Sports Medicine and Physical Fitness, vol. 50, no. 1, pp. 1–18, 2010.
- J. Cosnes, C. Gowerrousseau, P. Seksik, and A. Cortot, “Epidemiology and natural history of inflammatory bowel diseases,” Gastroenterology, vol. 140, no. 6, pp. 1785–1794, 2011.
- T. Lobstein, L. Baur, and R. Uauy, “Obesity in children and young people: a crisis in public health,” Obesity Reviews, vol. 5, supplement 1, pp. 4–104, 2004.
- A. Sonnenberg, “Occupational distribution of inflammatory bowel disease among German employees,” Gut, vol. 31, no. 9, pp. 1037–1040, 1990.
- P.-G. Persson, C.-E. Leijonmarck, O. Bernell, G. Hellers, and A. Ahlbom, “Risk indicators for inflammatory bowel disease,” International Journal of Epidemiology, vol. 22, no. 2, pp. 268–272, 1993.
- H. Boggild, F. Tuchsen, and E. Orhede, “Occupation, employment status and chronic inflammatory bowel disease in Denmark,” International Journal of Epidemiology, vol. 25, no. 3, pp. 630–637, 1996.
- I. Klein, S. Reif, H. Farbstein, A. Halak, and T. Gilat, “Preillness non dietary factors and habits in inflammatory bowel disease,” Italian Journal of Gastroenterology and Hepatology, vol. 30, no. 3, pp. 247–251, 1998.
- C. Cucino and A. Sonnenberg, “Occupational mortality from inflammatory bowel disease in the United States 1991–1996,” The American Journal of Gastroenterology, vol. 96, no. 4, pp. 1101–1105, 2001.
- J. Halfvarson, T. Jess, A. Magnuson et al., “Environmental factors in inflammatory bowel disease: a co-twin control study of a Swedish-Danish twin population,” Inflammatory Bowel Diseases, vol. 12, no. 10, pp. 925–933, 2006.
- S. S. Chan, R. Luben, A. Olsen, et al., “Body mass index and the risk for Crohn's disease and ulcerative colitis: data from a European Prospective Cohort Study (The IBD in EPIC Study),” The American Journal of Gastroenterology, vol. 108, no. 4, pp. 575–582, 2013.
- T. Hlavaty, J. Toth, T. Koller, et al., “Smoking, breastfeeding, physical inactivity, contact with animals, and size of the family influence the risk of inflammatory bowel disease: a Slovak case-control study,” United European Gastroenterology Journal, 2013.
- H. Khalili, A. N. Ananthakrishnan, G. G. Konijeti, et al., “Physical activity and risk of inflammatory bowel disease: prospective study from the Nurses' Health Study cohorts,” British Medical Journal, vol. 347, 2013.
- J. Bilski, A. I. Mazur-Bialy, M. Wierdak, et al., “The impact of physical activity and nutrition on inflammatory bowel disease: the potential role of cross talk between adipose tissue and skeletal muscle,” The Journal of Physiology and Pharmacology, vol. 64, no. 2, pp. 143–155, 2013.
- C. P. Loudon, V. Corroll, J. Butcher, P. Rawsthorne, and C. N. Bernstein, “The effects of physical exercise on patients with Crohn's disease,” The American Journal of Gastroenterology, vol. 94, no. 3, pp. 697–703, 1999.
- V. Ng, W. Millard, C. Lebrun, and J. Howard, “Low-intensity exercise improves quality of life in patients with Crohn's disease,” Clinical Journal of Sport Medicine, vol. 17, no. 5, pp. 384–388, 2007.
- N. Gupta, S. Khera, R. P. Vempati, R. Sharma, and R. L. Bijlani, “Effect of yoga based lifestyle intervention on state and trait anxiety,” Indian Journal of Physiology and Pharmacology, vol. 50, no. 1, pp. 41–47, 2006.
- I. Nathan, C. Norton, W. Czuber-Dochan, et al., “Exercise in individuals with inflammatory bowel disease,” Gastroenterology Nursing, vol. 36, no. 6, pp. 437–442, 2013.
- R. D'Incà, M. Varnier, C. Mestriner, D. Martines, A. D'Odorico, and G. C. Sturniolo, “Effect of moderate exercise on Crohn's disease patients in remission,” Italian Journal of Gastroenterology and Hepatology, vol. 31, no. 3, pp. 205–210, 1999.
- S. T. Nic, T. C. Raftery, O. McMahon, et al., “High prevalence of overweight and obesity in adults with Crohn's disease: associations with disease and lifestyle factors,” Journal of Crohn's and Colitis, vol. 7, no. 7, pp. e241–e248, 2013.
- H. Ploeger, J. Obeid, T. Nguyen et al., “Exercise and inflammation in pediatric Crohn's disease,” International Journal of Sports Medicine, vol. 33, no. 8, pp. 671–679, 2012.
- D. Chan, H. Robbins, S. Rogers, et al., “Inflammatory bowel disease and exercise: results of a Crohn's and Colitis UK survey,” Frontline Gastroenterology, vol. 5, no. 1, pp. 44–48, 2014.
- M. D. Cook, S. A. Martin, C. Williams, et al., “Forced treadmill exercise training exacerbates inflammation and causes mortality while voluntary wheel training is protective in a mouse model of colitis,” Brain, Behavior, and Immunity, pp. 46–56, 2013.
- X.-Z. Shi, J. H. Winston, and S. K. Sarna, “Differential immune and genetic responses in rat models of Crohn's colitis and ulcerative colitis,” American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 300, no. 1, pp. G41–G51, 2011.
- A. Saxena, E. Fletcher, B. Larsen, et al., “Effect of exercise on chemically-induced colitis in adiponectin deficient mice,” Journal of Inflammation, vol. 9, no. 1, article 30, 2012.
- L. Hoffman-Goetz, N. Pervaiz, N. Packer, and J. Guan, “Freewheel training decreases pro- and increases anti-inflammatory cytokine expression in mouse intestinal lymphocytes,” Brain, Behavior, and Immunity, vol. 24, no. 7, pp. 1105–1115, 2010.
- L. Hoffman-Goetz, R. J. Thorne, and M. E. Houston, “Splenic immune responses following treadmill exercise in mice,” Canadian Journal of Physiology and Pharmacology, vol. 66, no. 11, pp. 1415–1419, 1988.
- L. Hoffman-Goetz, P. A. Spagnuolo, and J. Guan, “Repeated exercise in mice alters expression of IL-10 and TNF-α in intestinal lymphocytes,” Brain, Behavior, and Immunity, vol. 22, no. 2, pp. 195–199, 2008.
- B. Luo, D. Xiang, D. C. Nieman, et al., “The effects of moderate exercise on chronic stress-induced intestinal barrier dysfunction and antimicrobial defense,” Brain, Behavior, and Immunity, 2013.
- M. D. Kappelman, S. L. Rifas-Shiman, K. Kleinman et al., “The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States,” Clinical Gastroenterology and Hepatology, vol. 5, no. 12, pp. 1424–1429, 2007.
- B. K. Pedersen and M. A. Febbraio, “Muscles, exercise and obesity: skeletal muscle as a secretory organ,” Nature Reviews Endocrinology, vol. 8, no. 8, pp. 457–465, 2012.
- A. L. Sheehan, B. F. Warren, M. W. L. Gear, and N. A. Shepherd, “Fat-wrapping in Crohn's disease: pathological basis and relevance to surgical practice,” British Journal of Surgery, vol. 79, no. 9, pp. 955–958, 1992.
- L. Peyrin-Biroulet, F. Gonzalez, L. Dubuquoy et al., “Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease,” Gut, vol. 61, no. 1, pp. 78–85, 2012.
- L. Peyrin-Biroulet, M. Chamaillard, F. Gonzalez et al., “Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?” Gut, vol. 56, no. 4, pp. 577–583, 2007.
- A. Kaser and H. Tilg, ““Metabolic aspects” in inflammatory bowel diseases,” Current Drug Delivery, vol. 9, no. 4, pp. 326–332, 2012.
- A. Batra, M. M. Heimesaat, S. Bereswill, et al., “Mesenteric fat-control site for bacterial translocation in colitis?” Mucosal Immunology, vol. 5, no. 5, pp. 580–591, 2012.
- C. Fink, I. Karagiannides, K. Bakirtzi, and C. Pothoulakis, “Adipose tissue and inflammatory bowel disease pathogenesis,” Inflammatory Bowel Diseases, vol. 18, no. 8, pp. 1550–1557, 2012.
- M. Drouet, L. Dubuquoy, P. Desreumaux, and B. Bertin, “Visceral fat and gut inflammation,” Nutrition, vol. 28, no. 2, pp. 113–117, 2012.
- S. C. Acedo, É. M. F. Gotardo, J. M. Lacerda, C. C. de Oliveira, P. de Oliveira Carvalho, and A. Gambero, “Perinodal adipose tissue and mesenteric lymph node activation during reactivated TNBS-colitis in rats,” Digestive Diseases and Sciences, vol. 56, no. 9, pp. 2545–2552, 2011.
- L. I. Kredel, A. Batra, T. Stroh et al., “Adipokines from local fat cells shape the macrophage compartment of the creeping fat in Crohn's disease,” Gut, vol. 62, no. 6, pp. 852–862, 2013.
- S. H. Jung, A. Saxena, K. Kaur, et al., “The role of adipose tissue-associated macrophages and T lymphocytes in the pathogenesis of inflammatory bowel disease,” Cytokine, vol. 61, no. 2, pp. 459–468, 2013.
- G. Monteleone, F. Pallone, and T. T. MacDonald, “Emerging immunological targets in inflammatory bowel disease,” Current Opinion in Pharmacology, vol. 11, no. 6, pp. 640–645, 2011.
- T. T. MacDonald, I. Monteleone, M. C. Fantini, and G. Monteleone, “Regulation of homeostasis and inflammation in the intestine,” Gastroenterology, vol. 140, no. 6, pp. 1768–1775, 2011.
- A. M. Mowat and C. C. Bain, “Mucosal macrophages in intestinal homeostasis and inflammation,” Journal of Innate Immunity, vol. 3, no. 6, pp. 550–564, 2011.
- I. C. Roberts-Thomson, J. Fon, W. Uylaki, A. G. Cummins, and S. Barry, “Cells, cytokines and inflammatory bowel disease: a clinical perspective,” Expert Review of Gastroenterology and Hepatology, vol. 5, no. 6, pp. 703–716, 2011.
- J. H. Cho, “The genetics and immunopathogenesis of inflammatory bowel disease,” Nature Reviews Immunology, vol. 8, no. 6, pp. 458–466, 2008.
- G. Shelley-Fraser, N. R. Borley, B. F. Warren, and N. A. Shepherd, “The connective tissue changes of Crohn's disease,” Histopathology, 2011.
- N. R. Borley, N. J. Mortensen, D. P. Jewell, et al., “The relationship between inflammatory and serosal connective tissue changes in ileal Crohn's disease: evidence for a possible causative link,” The Journal of Pathology, vol. 190, no. 2, pp. 196–202, 2000.
- I. Olivier, V. Théodorou, P. Valet et al., “Is Crohn's creeping fat an adipose tissue?” Inflammatory Bowel Diseases, vol. 17, no. 3, pp. 747–757, 2011.
- S. J. McCaskey, E. A. Rondini, I. M. Langohr, and J. I. Fenton, “Differential effects of energy balance on experimentally-induced colitis,” World Journal of Gastroenterology, vol. 18, no. 7, pp. 627–636, 2012.
- V. Ponemone, A. Keshavarzian, M. I. Brand, et al., “Apoptosis and inflammation: role of adipokines in inflammatory bowel disease,” Clinical and Translational Gastroenterology, vol. 1, no. 10, article e1, 2010.
- G. Biesiada, J. Czepiel, A. Ptak-Belowska, et al., “Expression and release of leptin and proinflammatory cytokines in patients with ulcerative colitis and infectious diarrhea,” The Journal of Physiology and Pharmacology, vol. 63, no. 5, pp. 471–481, 2012.
- M. Barbier, H. Vidal, P. Desreumaux et al., “Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases,” Gastroenterologie Clinique et Biologique, vol. 27, no. 11, pp. 987–991, 2003.
- M. Barbier, C. Cherbut, A. C. Aubé, H. M. Blottière, and J. P. Galmiche, “Elevated plasma leptin concentrations in early stages of experimental intestinal inflammation in rats,” Gut, vol. 43, no. 6, pp. 783–790, 1998.
- U. P. Singh, N. P. Singh, H. Guan, et al., “Leptin antagonist ameliorates chronic colitis in IL-10-/- mice,” Immunobiology, vol. 218, no. 12, pp. 1439–1451, 2013.
- K. Yamamoto, T. Kiyohara, Y. Murayama et al., “Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease,” Gut, vol. 54, no. 6, pp. 789–796, 2005.
- V. S. Rodrigues, M. Milanski, J. J. Fagundes, et al., “Serum levels and mesenteric fat tissue expression of adiponectin and leptin in patients with Crohn's disease,” Clinical & Experimental Immunology, vol. 170, no. 3, pp. 358–364, 2012.
- M. Chandran, S. A. Phillips, T. Ciaraldi, and R. R. Henry, “Adiponectin: more than just another fat cell hormone?” Diabetes Care, vol. 26, no. 8, pp. 2442–2450, 2003.
- A. Schaffler, J. Scholmerich, and C. Buchler, “Mechanisms of disease: adipocytokines and visceral adipose tissue—emerging role in intestinal and mesenteric diseases,” Nature Clinical Practice Gastroenterology & Hepatology, vol. 2, no. 2, pp. 103–111, 2005.
- A. Schäffler and H. Herfarth, “Creeping fat in Crohn's disease: travelling in a creeper lane of research,” Gut, vol. 54, no. 6, pp. 742–744, 2005.
- J. Weigert, F. Obermeier, M. Neumeier et al., “Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn's disease,” Inflammatory Bowel Diseases, vol. 16, no. 4, pp. 630–637, 2010.
- L. Valentini, E. K. Wirth, U. Schweizer et al., “Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease,” Nutrition, vol. 25, no. 2, pp. 172–181, 2009.
- K. Karmiris, I. E. Koutroubakis, and E. A. Kouroumalis, “Leptin, adiponectin, resistin, and ghrelin—implications for inflammatory bowel disease,” Molecular Nutrition and Food Research, vol. 52, no. 8, pp. 855–866, 2008.
- A. Schäffler and J. Schölmerich, “The role of adiponectin in inflammatory gastrointestinal diseases,” Gut, vol. 58, no. 3, pp. 317–322, 2009.
- A. Schäffler, J. Scholmerich, and C. Buchler, “Mechanisms of disease: adipocytokines and visceral adipose tissue—emerging role in intestinal and mesenteric diseases,” Nature Reviews Gastroenterology and Hepatology, vol. 2, no. 2, pp. 103–111, 2005.
- A. Zulian, R. Cancello, G. Micheletto et al., “Visceral adipocytes: old actors in obesity and new protagonists in Crohn's disease?” Gut, vol. 61, no. 1, pp. 86–94, 2012.
- G. Paul, A. Schäffler, M. Neumeier et al., “Profiling adipocytokine secretion from creeping fat in Crohn's disease,” Inflammatory Bowel Diseases, vol. 12, no. 6, pp. 471–477, 2006.
- K. Karmiris, I. E. Koutroubakis, and E. A. Kouroumalis, “The emerging role of adipocytokines as inflammatory mediators in inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 11, no. 9, pp. 847–855, 2005.
- A. Bortoli, N. Pedersen, D. Duricova et al., “Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003–2006,” Alimentary Pharmacology and Therapeutics, vol. 34, no. 7, pp. 724–734, 2011.
- B. K. Pedersen and B. Saltin, “Evidence for prescribing exercise as therapy in chronic disease,” Scandinavian Journal of Medicine and Science in Sports, vol. 16, no. 1, pp. 3–63, 2006.
- M. A. Febbraio, S. Rose-John, and B. K. Pedersen, “Is interleukin-6 receptor blockade the holy grail for inflammatory diseases?” Clinical Pharmacology and Therapeutics, vol. 87, no. 4, pp. 396–398, 2010.
- C. Keller, Y. Hellsten, A. Steensberg, and B. Klarlund Pedersen, “Differential regulation of IL-6 and TNF-α via calcineurin in human skeletal muscle cells,” Cytokine, vol. 36, no. 3-4, pp. 141–147, 2006.
- H. Ellingsgaard, I. Hauselmann, B. Schuler et al., “Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells,” Nature Medicine, vol. 17, no. 11, pp. 1481–1489, 2011.
- P. L. Brubaker and D. J. Drucker, “Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system,” Endocrinology, vol. 145, no. 6, pp. 2653–2659, 2004.
- D. J. Drucker, B. Yusta, R. P. Boushey, L. DeForest, and P. L. Brubaker, “Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis,” American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 276, no. 1, pp. G79–G91, 1999.
- M. S. Geier, D. Tenikoff, R. Yazbeck, G. W. McCaughan, C. A. Abbott, and G. S. Howarth, “Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV,” Journal of Cellular Physiology, vol. 204, no. 2, pp. 687–692, 2005.
- R. Yazbeck, G. S. Howarth, M. S. Geier, H.-U. Demuth, and C. A. Abbott, “Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice,” Frontiers in Bioscience, vol. 13, no. 18, pp. 6850–6858, 2008.
- A. R. Nielsen, R. Mounier, P. Plomgaard et al., “Expression of interleukin-15 in human skeletal muscle—effect of exercise and muscle fibre type composition,” The Journal of Physiology, vol. 584, no. 1, pp. 305–312, 2007.
- L. S. Quinn, B. G. Anderson, L. Strait-Bodey, A. M. Stroud, and J. M. Argués, “Oversecretion of interleukin-15 from skeletal muscle reduces adiposity,” American Journal of Physiology: Endocrinology and Metabolism, vol. 296, no. 1, pp. E191–E202, 2009.
- L. S. Quinn, L. Strait-Bodey, B. G. Anderson, J. M. Argilés, and P. J. Havel, “Interleukin-15 stimulates adiponectin secretion by 3T3-L1 adipocytes: Evidence for a skeletal muscle-to-fat signaling pathway,” Cell Biology International, vol. 29, no. 6, pp. 449–457, 2005.
- P. Boström, J. Wu, M. P. Jedrychowski et al., “A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis,” Nature, vol. 481, no. 7382, pp. 463–468, 2012.
- P. A. Bostrom, E. L. Graham, A. Georgiadi, et al., “Impact of exercise on muscle and nonmuscle organs,” IUBMB Life, vol. 65, no. 10, pp. 845–850, 2013.
- W. Aoi, Y. Naito, T. Takagi, et al., “A novel myokine, secreted protein acidic and rich in cysteine (SPARC), suppresses colon tumorigenesis via regular exercise,” Gut, vol. 62, no. 6, pp. 882–889, 2013.
- R. Vadan, L. S. Gheorghe, A. Constantinescu, and C. Gheorghe, “The prevalence of malnutrition and the evolution of nutritional status in patients with moderate to severe forms of Crohn's disease treated with Infliximab,” Clinical Nutrition, vol. 30, no. 1, pp. 86–91, 2011.
- J.-B. Wiroth, J. Filippi, S. M. Schneider et al., “Muscle performance in patients with Crohn's disease in clinical remission,” Inflammatory Bowel Diseases, vol. 11, no. 3, pp. 296–303, 2005.
- S. Schneider, R. Al-Jaouni, J. Filippi et al., “Sarcopenia is prevalent in patients with Crohn's disease in clinical remission,” Inflammatory Bowel Diseases, vol. 14, no. 11, pp. 1562–1568, 2008.
- D. R. van Langenberg, P. D. Gatta, B. Hill, et al., “Delving into disability in Crohn's disease: dysregulation of molecular pathways may explain skeletal muscle loss in Crohn's disease,” Journal of Crohn's and Colitis, 2013.
- R. Shamir, M. Phillip, and A. Levine, “Growth retardation in pediatric Crohn's disease: pathogenesis and interventions,” Inflammatory Bowel Diseases, vol. 13, no. 5, pp. 620–628, 2007.
- R. A. Frost and C. H. Lang, “Alteration of somatotropic function by proinflammatory cytokines,” Journal of Animal Science, vol. 82, pp. E100–E109, 2004.
- R. A. Frost, G. J. Nystrom, L. S. Jefferson, and C. H. Lang, “Hormone, cytokine, and nutritional regulation of sepsis-induced increases in atrogin-1 and MuRF1 in skeletal muscle,” American Journal of Physiology: Endocrinology and Metabolism, vol. 292, no. 2, pp. E501–E512, 2007.
- C. H. Lang, L. Hong-Brown, and R. A. Frost, “Cytokine inhibition of JAK-STAT signaling: a new mechanism of growth hormone resistance,” Pediatric Nephrology, vol. 20, no. 3, pp. 306–312, 2005.
- A. Ballinger, “Fundamental mechanisms of growth failure in inflammatory bowel disease,” Hormone Research, vol. 58, no. 1, pp. 7–10, 2002.
- A. B. Ballinger, O. Azooz, T. El-Haj, S. Poole, and M. J. G. Farthing, “Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis,” Gut, vol. 46, no. 5, pp. 694–700, 2000.
- L. B. Verdijk, B. G. Gleeson, R. A. M. Jonkers et al., “Skeletal muscle hypertrophy following resistance training is accompanied by a fiber type-specific increase in satellite cell content in elderly men,” Journals of Gerontology A, vol. 64, no. 3, pp. 332–339, 2009.
- S. M. Hindi, V. Mishra, S. Bhatnagar, et al., “Regulatory circuitry of TWEAK-Fn14 system and PGC-1a in skeletal muscle atrophy program,” The FASEB Journal, vol. 28, no. 3, pp. 1398–1411, 2013.
- M. M. Tajrishi, T. S. Zheng, L. C. Burkly, et al., “The TWEAK-Fn14 pathway: a potent regulator of skeletal muscle biology in health and disease,” Cytokine & Growth Factor Reviews, 2013.
- Z. Uhrin, S. Kuzis, and M. M. Ward, “Exercise and changes in health status in patients with ankylosing spondylitis,” Archives of Internal Medicine, vol. 160, no. 19, pp. 2969–2975, 2000.
- J. S. Siffledeen, K. Siminoski, H. Jen, and R. N. Fedorak, “Vertebral fractures and role of low bone mineral density in Crohn's disease,” Clinical Gastroenterology and Hepatology, vol. 5, no. 6, pp. 721–728, 2007.
- R. J. Robinson, T. Krzywicki, L. Almond et al., “Effect of a low-impact exercise program on bone mineral density in Crohn's disease: a randomized controlled trial,” Gastroenterology, vol. 115, no. 1, pp. 36–41, 1998.
- N. Lee, G. L. Radford-Smith, M. Forwood, J. Wong, and D. R. Taaffe, “Body composition and muscle strength as predictors of bone mineral density in Crohn's disease,” Journal of Bone and Mineral Metabolism, vol. 27, no. 4, pp. 456–463, 2009.
- N. Lee, G. Radford-Smith, and D. R. Taaffe, “Bone loss in Crohn's disease: exercise as a potential countermeasure,” Inflammatory Bowel Diseases, vol. 11, no. 12, pp. 1108–1118, 2005.
- J. Bilski, G. Manko, T. Brzozowski, et al., “Effects of exercise of different intensity on gut peptides, energy intake and appetite in young males,” Annals of Agricultural and Environmental Medicine, vol. 20, no. 4, pp. 787–793, 2013.
- J. Jaworek, J. Bonior, S. J. Konturek, J. Bilski, A. Szlachcic, and W. W. Pawlik, “Role of leptin in the control of postprandial pancreatic enzyme secretion,” The Journal of Physiology and Pharmacology, vol. 54, no. 4, pp. 591–602, 2003.
- Z. Warzecha, A. Dembiński, P. Ceranowicz et al., “Influence of leptin administration on the course of acute ischemic pancreatitis,” The Journal of Physiology and Pharmacology, vol. 53, no. 4, pp. 775–790, 2002.
- A. Ballinger, “Divergency of leptin response in intestinal inflammation,” Gut, vol. 44, no. 5, pp. 588–589, 1999.
- I. M. Minderhoud, M. Samsom, and B. Oldenburg, “Crohn's disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue?” World Journal of Gastroenterology, vol. 13, no. 14, pp. 2089–2093, 2007.
- D. R. van Langenberg and P. R. Gibson, “Factors associated with physical and cognitive fatigue in patients with Crohn's Disease: a cross-sectional and longitudinal Study,” Inflammatory Bowel Diseases, vol. 20, no. 1, pp. 115–125, 2014.
- F. Blondel-Kucharski, C. Chircop, P. Marquis et al., “Health-related quality of life in Crohn's disease: a prospective longitudinal study in 231 patients,” The American Journal of Gastroenterology, vol. 96, no. 10, pp. 2915–2920, 2001.
- I. M. Minderhoud, B. Oldenburg, J. A. Wismeijer, G. P. van Berge Henegouwen, and A. J. P. M. Smout, “IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior,” Digestive Diseases and Sciences, vol. 49, no. 3, pp. 469–474, 2004.
- E. Ball, “Exercise guidelines for patients with inflammatory bowel disease,” Gastroenterology Nursing, vol. 21, no. 3, pp. 108–111, 1998.
- M. J. Gibala, J. P. Little, M. J. Macdonald, and J. A. Hawley, “Physiological adaptations to low-volume, high-intensity interval training in health and disease,” The Journal of Physiology, vol. 590, no. 5, pp. 1077–1084, 2012.
- K. A. Burgomaster, K. R. Howarth, S. M. Phillips et al., “Similar metabolic adaptations during exercise after low volume sprint interval and traditional endurance training in humans,” The Journal of Physiology, vol. 586, no. 1, pp. 151–160, 2008.
- I. Janssen and A. G. LeBlanc, “Systematic review of the health benefits of physical activity and fitness in school-aged children and youth,” International Journal of Behavioral Nutrition and Physical Activity, vol. 7, article 40, 2010.
- W. J. Tremaine, L. J. Timmons, E. V. Loftus Jr. et al., “Age at onset of inflammatory bowel disease and the risk of surgery for non-neoplastic bowel disease,” Alimentary Pharmacology and Therapeutics, vol. 25, no. 12, pp. 1435–1441, 2007.
- N. H. Yeo, J. Woo, K. O. Shin, et al., “The effects of different exercise intensity on myokine and angiogenesis factors,” The Journal of Sports Medicine and Physical Fitness, vol. 52, no. 4, p. 448, 2012.
- S. Elsenbruch, J. Langhorst, K. Popkirowa et al., “Effects of mind-body therapy on quality of life and neuroendocrine and cellular immune functions in patients with ulcerative colitis,” Psychotherapy and Psychosomatics, vol. 74, no. 5, pp. 277–287, 2005.